8% reported weight loss · 2.6% loss with placebo · 56 weeks
3 mg once daily
Adults with obesity, or overweight plus a weight-related condition, without diabetes
Prespecified full-analysis-set analysis using last observation carried forward (LOCF); not a modern treatment-policy estimand FDA-approved for adult weight management (Saxenda)
Safety context
Gastrointestinal symptoms were common; gallbladder events and pancreatitis occurred.
Limitations: Older LOCF analysis differs from modern policy estimands.
Originator type 2 diabetes brand in the U.S. and Europe; not the 3 mg Saxenda obesity product. · injection
Novo Nordisk · Originator; manufacturer of Saxenda and Victoza.; Hikma Pharmaceuticals USA · FDA-approved generic liraglutide supplier referencing Victoza; this is a diabetes product, not the Saxenda obesity dose.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Source-provided sequence and chemical modification diagram of Liraglutide.
Shown: Active peptide; formulation excluded.
A two-dimensional sequence diagram, not a three-dimensional conformation. Amino-acid abbreviations stand for residues; connecting lines represent peptide connectivity. The diagram includes the Lys-linked glutamyl/palmitoyl modification and the 31-residue peptide.
A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history9 selected milestones
Liraglutide · compound history across indications
Selected early human publications, phase 3 development, and later approvals. The 2002 publication is not a verified first-human-dose date; earlier discovery and studies may be missing.
Publication
Early human pharmacology results published (NN2211)
A repeated-dose study of NN2211, later named liraglutide, reported a pharmacokinetic profile supporting once-daily administration. This is a publication month, not a first-human-dose date.
The 52-week monotherapy comparison with glimepiride was published online in The Lancet, before the February 2009 print issue and the 2010 U.S. approval.
Hikma received approval for generic liraglutide injection for type 2 diabetes; this event does not establish approval of a generic Saxenda obesity product.
